SCHEMBL3511082

SCHEMBL3511082

Cc1csc(CNC(=O)c2cc(C(N)=O)cc(-c3ccncc3)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
HSP90AA1 P07900 1/20 0.43
GAA P10253 1/20 0.43
SLC5A7 Q9GZV3 1/20 0.43
MAPT P10636 1/20 0.43
NAMPT P43490 1/20 0.42
ROCK2 O75116 4/20 0.42
GRK2 P25098 1/20 0.42
WDR5 P61964 4/20 0.41
GSK3B P49841 3/20 0.40
ROCK1 Q13464 3/20 0.40
AURKA O14965 2/20 0.40
MAPK1 P28482 2/20 0.40
PRKACA P17612 2/20 0.40
GSK3A P49840 2/20 0.40
PRKX P51817 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
RPS6KA5 O75582 1/20 0.40
MAP4K4 O95819 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3686716 0.89 RAB9A (0.48) RAB9ANPC1HSP90AA1GAASLC5A7
SCHEMBL3509902 0.89 TSHR (0.46) RAB9ANPC1HSP90AA1SLC5A7MAPT
SCHEMBL3509630 0.84 ADORA2A (0.46) RAB9ANPC1HSP90AA1SLC5A7NAMPT
SCHEMBL3513838 0.84 MAPK1 (0.41) RAB9ANPC1HSP90AA1GAASLC5A7
SCHEMBL3647405 0.82 ENPP2 (0.52) RAB9ANPC1HSP90AA1GAASLC5A7
SCHEMBL3510035 0.82 RAB9A (0.40) RAB9ANPC1HSP90AA1SLC5A7NAMPT
SCHEMBL3508887 0.82 MAPK1 (0.41) RAB9ANPC1HSP90AA1SLC5A7NAMPT
SCHEMBL3641877 0.79 NPC1 (0.41) RAB9ANPC1GAAMAPT
SCHEMBL3511239 0.78 SLC5A7 (0.46) RAB9ANPC1HSP90AA1SLC5A7NAMPT
SCHEMBL3509460 0.78 SLC5A7 (0.45) RAB9ANPC1HSP90AA1SLC5A7NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-11-11 US disclosed
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP disclosed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY BACE1, BACE2, APP RAB9A 3199/4885NPC1 204/4885HSP90AA1 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.